Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer
NCT04918836 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2021-06-09
Summary
A prospective, observational, single-center study to determine the proportion of patients who have or will develop changes in biological markers of immunity during immunotherapy treatment.
Conditions
Sponsors & Collaborators
-
University Hospital, Brest
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-08
- Primary Completion
- 2021-10-08
- Completion
- 2022-10-08
Countries
- France
Study Locations
More Related Trials
-
Immunological Profile Changes In Patients With Advanced Non-Small Cell Lung Cancer
NCT04187768 ·Status: COMPLETED
-
Immune Response to Immunotherapy in Lung Cancer: Study of Sputum and Blood Samples
NCT07163507 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
NCT05965557 ·Status: RECRUITING
-
Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.
NCT03397355 ·Status: UNKNOWN
-
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNG
NCT04790682 ·Status: RECRUITING ·Phase: NA
-
Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers
NCT03658460 ·Status: COMPLETED
-
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
NCT03578185 ·Status: RECRUITING
-
Immune Response in Lung Cancer
NCT01955343 ·Status: COMPLETED
-
The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer
NCT06287320 ·Status: RECRUITING
-
Prediction Model of ICIs Combined With Chemotherapy in Advanced NSCLC
NCT05725915 ·Status: UNKNOWN
-
Exploratory Biomarker Analysis of Neoadjuvant Chemoimmunotherapy Followed by Pulmonary Resection in Stage II-III Non-Small Cell Lung Cancer
NCT06907160 ·Status: RECRUITING
-
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator
NCT04352335 ·Status: COMPLETED
-
Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC
NCT06613308 ·Status: NOT_YET_RECRUITING
-
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
NCT04720339 ·Status: RECRUITING ·Phase: NA
-
Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
NCT04300062 ·Status: RECRUITING ·Phase: NA
-
Tumor Mutational Burden in Lung Cancer Patients
NCT04289259 ·Status: TERMINATED
-
Investigation on Predictive Molecular Markers of Efficacy for Front-line Immunochemotherapy in Advanced NSCLC
NCT04858828 ·Status: UNKNOWN
-
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
NCT05288569 ·Status: UNKNOWN
-
Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC
NCT04886401 ·Status: RECRUITING
-
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
NCT06833229 ·Status: RECRUITING
-
Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer
NCT02202655 ·Status: UNKNOWN
-
Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration in NSCL Cancer Patients
NCT04880382 ·Status: TERMINATED ·Phase: PHASE2
-
Circulating Immune Markers for Prognostic Evaluation in Postoperative Lung Cancer Patients
NCT07242482 ·Status: NOT_YET_RECRUITING
-
'Lung Health Check' Biomarker Study
NCT04957433 ·Status: UNKNOWN
-
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
NCT05641870 ·Status: UNKNOWN